Company adds Johns Hopkins leader in atypical parkinsonism to support clinical adoption of neuropacs™ AIDP, its AI-enabled MRI software for differentiating MSAp and PSP from Parkinson’s disease.
GAINESVILLE, FL – Neuropacs™ Corp., an AI-enabled imaging company focused on software tools that support the evaluation of neurodegenerative diseases, today announced that Alexander Pantelyat, MD, FAAN, has agreed to serve on the company’s Board of Advisors, effective immediately.
Dr. Pantelyat is an Associate Professor of Neurology at the Johns Hopkins University School of Medicine, where he has been on faculty since 2014. He founded and directs the Johns Hopkins Atypical Parkinsonism Center, a multidisciplinary research, clinical, and education program for patients with progressive supranuclear palsy (PSP), corticobasal syndrome/degeneration, multiple system atrophy (MSA), and dementia with Lewy bodies. He also co-founded and directs the Johns Hopkins Center for Music & Medicine. He has been continuously funded by the NIH since 2016. His research includes an NINDS Parkinson’s Disease Biomarkers Program project on biomarkers that distinguish PSP from Parkinson’s disease, and multicenter 4-repeat tauopathy research that includes MRI-based research work in PSP and CBD. He has authored over 150 publications and is a former co-director of the Johns Hopkins Movement Disorders Fellowship Program. He is a Fellow of the American Academy of Neurology, and he has been recognized as an Alafouzos Family Scholar of the Johns Hopkins Center for Innovative Medicine and as a Baltimore Magazine “Top Doctor.” Dr. Pantelyat received his medical degree from Temple University School of Medicine. He completed his neurology residency at the Hospital of the University of Pennsylvania and his fellowship training in movement disorders at the University of Pennsylvania and the Philadelphia VA Medical Center.
“Dr. Pantelyat is an outstanding addition to our Board of Advisors. Helping clinicians differentiate MSAp and PSP from Parkinson’s disease is exactly what neuropacs™ AIDP was built to do, and few neurologists have devoted more of their career to patients with atypical parkinsonism,” commented Dr. Martin Handfield, President and CEO of Neuropacs Corp. He added, “His experience building multidisciplinary programs at Johns Hopkins, and his work on imaging and biomarkers in clinical trial design, will be invaluable as we expand pharma and clinical adoption, and support research partners.”
“Patients with atypical parkinsonism often face a long and winding path to an accurate diagnosis,” commented Dr. Pantelyat. He added, “I’m excited to help Neuropacs bring objective, imaging-based information into neurological practice, where it can support clinicians alongside a thorough clinical evaluation.”
For more information, visit neuropacs.com.
About Neuropacs™ Corp.
Neuropacs™ Corp. is an AI-enabled imaging company focused on developing software tools to support the evaluation of neurodegenerative diseases. Automated Imaging Diagnostics LLC, is a wholly owned subsidiary of Neuropacs Corp. Its platform leverages advanced imaging analytics to provide insights for clinical and research applications. https://neuropacs.com/
About neuropacs™
neuropacs™ is a prescription device that analyzes patient-specific data to aid in the diagnosis of Parkinsonian syndromes. The test requires a single, non-invasive, and radiotracer-free diffusion MRI scan, which can be acquired using standard diffusion MRI sequences available on 3 Tesla clinical MRI systems from Siemens, GE Healthcare, and Philips. The brain scan is analyzed using a rigorously validated free-water imaging model and machine learning algorithm. The device provides a classification report based on degenerative brain patterns of multiple system atrophy Parkinsonian variant (MSAp) and progressive supranuclear palsy (PSP) to help neuroradiologists and/or neurologists in differentiating these diseases from Parkinson’s disease (PD). Important Safety Information: The neuropacs™ system is intended to provide supplemental information and is not a standalone diagnostic device. Results should be interpreted in conjunction with clinical evaluation and other diagnostic testing. This device does not rule out other potential causes of Parkinsonism symptoms or signs and is intended to be used after all other potential causes of Parkinsonism symptoms (such as dementia with Lewy bodies, vascular Parkinsonism, drug-induced Parkinsonism, and corticobasal degeneration/syndrome) have been ruled out by trained clinicians on the basis of clinical, neurological, and other laboratory tests. Patient management decisions should not be based solely on neuropacs™ output.
Forward-Looking Statements
This communication includes express and implied “forward-looking statements.” Forward-looking statements include all statements that are not historical facts and in some cases, can be identified by terms such as “may,” “might,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “objective,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue,” “ongoing,” or the negative of these terms, or other comparable terminology intended to identify statements about the future. By their nature, these statements are subject to numerous risks and uncertainties, that could cause actual results, performance or achievement to differ materially and adversely from those anticipated or implied in the statements. You should not rely upon forward-looking statements as predictions of future events. Although our management believes that the expectations reflected in our statements are reasonable, we cannot guarantee that the future results, performance, or events and circumstances described in the forward-looking statements will be achieved or occur. Recipients are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date such statements are made and should not be construed as statements of fact. We undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, any future presentations, or otherwise, except as required by applicable law.
Follow the Conversation
Stay up to date with the latest company announcements and industry insights by following @neuropacs on LinkedIn, X, and Instagram.
Media Contact: Martin Handfield, President & CEO, [email protected]

